Jean-Francois Rossi
Chief Executive Officer Innomune
Seminars
Wednesday 25th February 2026
Advancing Next-Generation NK Platforms through Antibody-Guided CAR-like NK Cells
12:30 pm
- Showcasing a CAR-like NK platform that achieves targeted cytotoxicity via monoclonal antibody attachment, eliminating the need for genetic modification
- Presenting preclinical data validating the platform’s potent CD16-mediated activity
New Data
